NCT07739017 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07739017
Title	OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma (OPAL)
Acronym	OPAL
Recruitment	Not yet recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Olivia Newton-John Cancer Research Institute
Indications	IDH-wildtype glioblastoma
Therapies	CT-179
Age Groups:	adult \| senior
Covered Countries	AUS

Facility	Status	City	State	Zip	Country	Details
Royal Brisbane and Women's Hospital		Herston	Queensland	4006	Australia	Details
Austin Health		Heidelberg	Victoria	3084	Australia	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07739017Clinical Trial Detail